nvasive, simple and reliable detection of Prostate and Bladder Cancer. Currently, routine screening of the general public for bladder cancer is not recommended by any major professional organization. This is due to lack of a sensitive and specific test that will detect bladder cancer in an individual without clinical symptoms of disease. Current screening for Prostate Cancer by digital rectal examination (DRE) and Prostate Specific Antigen (PSA) blood levels result in low cancer predictive ability and lead to increased numbers of potentially unnecessary invasive biopsy procedures.
Prostate cancer is the second leading cause of cancer death in American men and over 72,000 men and women are estimated to be diagnosed with Bladder Cancer in the U.S. in 2013. Mortality from Prostate and Bladder Cancer strongly correlates with the stage of disease upon diagnosis. Therefore, the ability to detect early-stage cancer before clinical presentation would have a dramatic effect upon patient outcomes.
About NuView’s VPAC1 Technology platform
Previous research by Dr. Thakur and others has revealed that Breast, Prostate, and other cancer cells express the VPAC1 oncogene product in high density on their cell surface. This expression occurs at a very early stage in oncogenic transformation, well before changes in cell morphology. For Prostate Cancer cells, VPAC1 expression occurs well before the elevation of Prostate Specific Antigen (PSA).
This VPAC1-based urine screen (TP4303) utilizes the same technology as NLS-VPAC1 ([Cu-64]-TP3805), our positron emission tomography (PET)-based molecular imaging diagnostic. Recently, Dr. Thakur presented results from a PET imaging study in Breast Cancer patients where NLS-VPAC1 unequivocally identified 100% (n=19) of the malignant lesions, irrespective of their hormonal status. NLS-VPAC1 also detected all (100%) sentinel lymph nodes (n=4). NuView is developing NLS-VPAC1 for the identification and localiza
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. NuView Life Sciences and Thomas Jefferson University Sign Agreement for Exclusive Development and Commercialization Rights to Novel Prostate Cancer Diagnostic2
. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC13
. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal4
. Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding5
. Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit6
. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology7
. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors8
. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA9
. Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers10
. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities11
. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update